Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
CLVS's Cash to Debt is ranked higher than
81% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. CLVS: No Debt )
CLVS' s 10-Year Cash to Debt Range
Min: 0.91   Max: No Debt
Current: No Debt

Equity to Asset 0.75
CLVS's Equity to Asset is ranked higher than
77% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CLVS: 0.75 )
CLVS' s 10-Year Equity to Asset Range
Min: 0.75   Max: 0.75
Current: 0.75

Interest Coverage No Debt
CLVS's Interest Coverage is ranked higher than
84% of the 408 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CLVS: No Debt )
CLVS' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

Z-Score: 4.99
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -16.98
CLVS's ROE (%) is ranked higher than
73% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -20.60 vs. CLVS: -16.98 )
CLVS' s 10-Year ROE (%) Range
Min: -55.42   Max: -16.98
Current: -16.98

-55.42
-16.98
ROA (%) -13.01
CLVS's ROA (%) is ranked higher than
74% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. CLVS: -13.01 )
CLVS' s 10-Year ROA (%) Range
Min: -144.39   Max: -13.01
Current: -13.01

-144.39
-13.01
ROC (Joel Greenblatt) (%) -8771.41
CLVS's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -243.56 vs. CLVS: -8771.41 )
CLVS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -8771.41   Max: -2879.01
Current: -8771.41

-8771.41
-2879.01
» CLVS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

CLVS Guru Trades in Q2 2013

Steven Cohen 693,729 sh (New)
Jim Simons 21,400 sh (+80.2%)
Louis Moore Bacon Sold Out
» More
Q3 2013

CLVS Guru Trades in Q3 2013

Steven Cohen 1,087,375 sh (+56.74%)
Jim Simons 14,200 sh (-33.64%)
» More
Q4 2013

CLVS Guru Trades in Q4 2013

Steven Cohen 1,166,700 sh (+7.3%)
Jim Simons Sold Out
» More
Q1 2014

CLVS Guru Trades in Q1 2014

Steven Cohen 458,238 sh (-60.72%)
» More
» Details

Insider Trades

Latest Guru Trades with CLVS

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2012-12-31 Sold Out 0.06%$11.65 - $22.5 $ 37.01110%0
John Burbank 2012-09-30 New Buy0.06%$13.55 - $23.15 $ 37.0195%60900
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.80
CLVS's P/B is ranked higher than
85% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 5.51 vs. CLVS: 2.80 )
CLVS' s 10-Year P/B Range
Min: 0   Max: 7.6
Current: 2.8

0
7.6
P/S 83.33
CLVS's P/S is ranked higher than
57% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 19.16 vs. CLVS: 83.33 )
CLVS' s 10-Year P/S Range
Min: 0   Max: 133.3
Current: 83.33

0
133.3
EV-to-EBIT -11.45
CLVS's EV-to-EBIT is ranked higher than
79% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CLVS: -11.45 )
CLVS' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -11.45

Current Ratio 12.81
CLVS's Current Ratio is ranked higher than
92% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. CLVS: 12.81 )
CLVS' s 10-Year Current Ratio Range
Min: 0.86   Max: 31.09
Current: 12.81

0.86
31.09
Quick Ratio 12.81
CLVS's Quick Ratio is ranked higher than
92% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. CLVS: 12.81 )
CLVS' s 10-Year Quick Ratio Range
Min: 0.86   Max: 31.09
Current: 12.81

0.86
31.09

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.50
CLVS's Price/Net Cash is ranked higher than
85% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 65.19 vs. CLVS: 8.50 )
CLVS' s 10-Year Price/Net Cash Range
Min: 2.45   Max: 15.96
Current: 8.5

2.45
15.96
Price/Net Current Asset Value 8.40
CLVS's Price/Net Current Asset Value is ranked higher than
84% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 44.88 vs. CLVS: 8.40 )
CLVS' s 10-Year Price/Net Current Asset Value Range
Min: 2.45   Max: 15.71
Current: 8.4

2.45
15.71
Price/Tangible Book 8.00
CLVS's Price/Tangible Book is ranked higher than
72% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 8.78 vs. CLVS: 8.00 )
CLVS' s 10-Year Price/Tangible Book Range
Min: 2.39   Max: 15.03
Current: 8

2.39
15.03

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Clovis Oncology Inc is a biopharmaceutical company. The Company is engaged in acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide